Please note that the details of this Challenge are no longer open. This challenge is withdrawn and is no longer accepting new submissions. You can:
Challenge Intestinal Carcinoid and Pancreatic Neuroendocrine Tumor Cell Lines Needed – Year Two
Intestinal Carcinoid and Pancreatic Neuroendocrine Tumor Cell Lines Needed – Year Two
Award: $600,000 USD
Deadline: Withdrawn
Active Solvers: 135
Posted: Jul 06 2015
Challenge ID: 9933756
Share Challenge Share

The lack of well-validated and widely accepted cell lines derived from intestinal carcinoid and pancreatic neuroendocrine tumors (PNET) is a significant barrier for research and development of new therapies. The Neuroendocrine Tumor Research Foundation, previously named as the Caring for Carcinoid Foundation, therefore wishes to launch a second Challenge to stimulate a concerted effort to create a “collection” of well-characterized cell lines that faithfully replicate tumor characteristics and genetics. The Foundation has partnered with the Rare Cancer Research Foundation (RCRF), a foundation dedicated to curing rare cancers through strategic investments and innovative collaborations, and the American Type Culture Collection (ATCC), the world’s largest non-profit cell line repository, to establish a Neuroendocrine Tumor Cell Line collection in their catalog.

This is a Reduction-to-Practice Challenge that requires written documentation, detailed description of each cell line, and sample delivery.


This Challenge is intended to encourage innovative approaches to establishing new cell lines from primary tumors that grow slowly in vivo and to publicize new methods as well as availability of the new cell lines for broad, unrestricted use.

To stimulate development of new carcinoid and PNET cell lines, the Foundation is pleased to announce its second open competition for up to ten individual prizes: Developers of the first new cell lines in each disease (intestinal carcinoid and PNET) will receive $100,000 each and developers of the second, third, fourth, and fifth new cell lines in each disease will receive $50,000 each. Individual creators are eligible for one (the first cell line from either disease) or up to ten prizes (the first, second, third, fourth, and fifth cell lines from both diseases). To be eligible for the prize(s), the submitted cell lines must be:

  1. Approved by the Neuroendocrine Tumor Research Foundation, according to the criteria specified in the Detailed Description & Requirements, and
  2. Deposited into the ATCC repository for unrestricted distribution to qualified investigators under an agreement approved by the Neuroendocrine Tumor Research Foundation.

Discover how to submit your cell lines in the Detailed Description & Requirements of the Challenge.

Entrants to the first Challenge (9933510) will be evaluated independently of the submissions received for this current Challenge. Previous Solvers are encouraged to submit newly developed cell lines and are eligible for all prizes specified above. 

Submissions to this Challenge must be received by 11:59 PM (U.S. Eastern Time) on July 6, 2016.

What is InnoCentive?
InnoCentive is the global innovation marketplace where creative minds solve some of the world's most important problems for cash awards up to $1 million. Commercial, governmental and humanitarian organizations engage with InnoCentive to solve problems that can impact humankind in areas ranging from the environment to medical advancements.

What is an RTP Challenge?

An InnoCentive RTP (Reduction to Practice) Challenge is a prototype that proves an idea, and is similar to an InnoCentive Theoretical Challenge in its high level of detail. However, an RTP requires the Solver to submit a validated solution, either in the form of original data or a physical sample. Also the Seeker is allowed to test the proposed solution. For details about treatment of IP rights, please see the Challenge-Specific Agreement.

Share This Challenge